FDA OK Lifts Critical Therapeutics
Critical Therapeutics(CRTX Quote) bounded 30% Thursday morning after specialty pharmaceutical company Dey announced the Food and Drug Administration had approved a new drug application (NDA) for the asthma treatment Zyflo CR.
The NDA is for twice-daily, extended-release tablets, also known as zileuton. Critical Therapeutics, a Lexington, Mass. biopharmaceutical company, and Dey, which is affiliated with Germany's Merck KGaA, will co-market the drug according to an agreement they made in March.
Zyflo and Zyflo CR are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children age 12 and older, the companies said. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,426.46 | 1,115.31 | 2,238.81 | 36.67 |
Oil *
72.95
|
|
UP
97.57
|
UP
12.84
|
UP
27.12
|
UP
1.21
|
10 Yr
3.67%
SPDR Gold
107.20
|
|
+0.94%
|
+1.16%
|
+1.23%
|
+3.41%
|
Data delayed 20 minutes |


Connect with TheStreet